FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
29 | INNOVATIVE THERAPEUTIC STRATEGIES IN GENODERMATOSIS: AN ITALIAN MULTICENTRE STUDY F. Pavan1, F. Cassalia2, S. Giordano3, A. Gelmetti4, L. Ventura5, F. Caroppo2, A. Bassi6, F. Martorana7, R. Balestri8, A. Guglielmo9, F. Ambrogio10, A. Bonvicino3, I. Neri4, P. Quaglino3, A. Belloni Fortina11 | 1Pediatrics Unit, Department of Women’s and Child’s Health (SDB), University of Padua, Italy; 2Dermatology Unit, Department of Medicine (DIMED), University of Padua, Italy; 3Department of Medical Sciences, Section of Dermatology, University of Turin, Italy; 4Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Italy; 5Department of Statistical Science, University of Padua, Italy; 6Unit of Dermatology, Azienda USL Toscana Nord Ovest, Lucca, Italy; 7Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II; 8Division of Dermatology, Outpatient Consultation for Rare Diseases, APSS, Trento, Italy; 9Institute of Dermatology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy; 10Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari “Aldo Moro”, Italy; 11Pediatric Dermatology Department of Women’s and Child’s Health (SDB), University of Padua, Italy
89PDF: 20 -
31 | DRUG ECONOMIC ANALYSIS OF THE DOSE SPACING OF BIOLOGICAL DRUGS IN ATOPIC DERMATITIS AND PSORIASIS A. Filoni1, L. Pietroleonardo1, P. Stasi2, M. Spagnolo2, F. Scicchitano2, S. Pelle3, M. Congedo1 | 1UOSVD Dermatology and Allergology, Hospital Vito Fazzi, Lecce, Italy; 2Servizio Farmaceutico Distrettuale. Asl Lecce, Italy; 3Dermatology Outpatient Unit, Asl Lecce, Italy
77PDF: 24 -
New and emerging therapies in cutaneous T-cell lymphoma
1213PDF: 686HTML: 109 -
Measuring the impact of pruritus in patients with epidermolysis bullosa: evaluation with an itch-specific instrument
1208PDF: 400APPENDIX S1: 214HTML: 19 -
CD4/CD8 double-negative mycosis fungoides: a review
3327PDF: 658SUPPLEMENTARY: 132HTML: 37 -
67 | LEBRIKIZUMAB FOR PAEDIATRIC PATIENTS AGED ≥6 MONTHS WITH MODERATE-TO-SEVERE AD: PHASE 3 ADORABLE-1 WEEK-16 RESULTS L. Stingeni1, L. Eichenfield2, J. Ornelas3, V. Prajapati4, C. Yang5, A. Tanaka6, S. Weidinger7, C. Flohr8, E. Swanson9, L. Martin10, S. Daveiga11, R. Gontijo Lima11, H. Elmaraghy11, E. Pierce11, P. Sen11, G. Gallo11, M. Piruzeli11, A. Larkin11, M. Grau12, Y. Mihaylov12, A. Paller13 | 1Dermatology Section, Department of Medicine and Surgery, University of Perugia, Italy; 2Departments of Dermatology and Pediatrics, University of California San Diego School of Medicine, La Jolla, California, USA; 3Department of Dermatology, Integrative Skin Science and Research, Sacramento, California, USA; 4Dermatology Research Institute, Skin Health & Wellness Centre, Probity Medical Research, and University of Calgary, Calgary, Canada; 5Chang Gung University College of Medicine, Taoyuan, Taiwan; 6Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; 7Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Lübeck, Germany; 8Department of Dermatology and Population Health Sciences, King’s College London, UK; 9Ada West Dermatology, St Luke’s Children’s Hospital Idaho, USA; 10School of Clinical Medicine, UNSW Sydney & Dermatology Department, Sydney Children’s Hospital, Sydney, Australia; 11Eli Lilly and Company, Indianapolis, Indiana, USA; 12Almirall R&D, S.A., Barcelona, Spain; 13Dermatology and Infectious Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
88PDF: 36
